JP2006509830A - 癌予防用ハイブリッド細胞ワクチンの調製および投与 - Google Patents

癌予防用ハイブリッド細胞ワクチンの調製および投与 Download PDF

Info

Publication number
JP2006509830A
JP2006509830A JP2004563716A JP2004563716A JP2006509830A JP 2006509830 A JP2006509830 A JP 2006509830A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2006509830 A JP2006509830 A JP 2006509830A
Authority
JP
Japan
Prior art keywords
cell
cells
dendritic
cancer
precancerous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004563716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509830A5 (enExample
Inventor
典也 大野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006509830A publication Critical patent/JP2006509830A/ja
Publication of JP2006509830A5 publication Critical patent/JP2006509830A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004563716A 2002-12-16 2003-12-16 癌予防用ハイブリッド細胞ワクチンの調製および投与 Pending JP2006509830A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/320,779 US20040115224A1 (en) 2002-12-16 2002-12-16 Preparation and administration of hybrid cell vaccines for the prevention of cancer
PCT/US2003/040284 WO2004057968A1 (en) 2002-12-16 2003-12-16 Preparation and administration of hybrid cell vaccines for the prevention of cancer

Publications (2)

Publication Number Publication Date
JP2006509830A true JP2006509830A (ja) 2006-03-23
JP2006509830A5 JP2006509830A5 (enExample) 2007-02-08

Family

ID=32506941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563716A Pending JP2006509830A (ja) 2002-12-16 2003-12-16 癌予防用ハイブリッド細胞ワクチンの調製および投与

Country Status (7)

Country Link
US (1) US20040115224A1 (enExample)
EP (1) EP1583424A4 (enExample)
JP (1) JP2006509830A (enExample)
AU (1) AU2003301023A1 (enExample)
CA (1) CA2508209A1 (enExample)
IL (1) IL169124A0 (enExample)
WO (1) WO2004057968A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155514A0 (en) * 2000-10-20 2003-11-23 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JP2007528375A (ja) * 2004-03-02 2007-10-11 典也 大野 癌の治療および予防用雑種細胞ワクチンの方法および組成物
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
CA2676808C (en) * 2007-04-27 2016-08-02 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf)
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
JP2022542745A (ja) * 2019-05-27 2022-10-07 錦高キャピタル株式会社 樹状細胞ベースの癌ワクチン及びその調製方法
US20240002798A1 (en) * 2020-11-17 2024-01-04 Research & Business Foundation Sungkyunkwan University Method for preparing immunogenicity-enhanced cd103+ fcgr3+ dendritic cell by treatment with interleukin-33 and pharmaceutical composition comprising same dendritic cell for cancer immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059073A2 (en) * 2000-02-11 2001-08-16 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
JP2001526622A (ja) * 1994-07-18 2001-12-18 シドニー キンメル キャンサー センター インビボでの腫瘍細胞免疫を高めるための組成物および方法
JP2002501377A (ja) * 1997-04-15 2002-01-15 ダナ−ファーバー キャンサー インスティテュート インク． 樹状細胞ハイブリッド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85919A1 (fr) * 1984-06-07 1986-01-14 Marginvest Sa Holding Procede de preparation d'un agent absorbant et adsorbant,et agent absorbant et adsorbant ainsi obtenu
US20020041868A1 (en) * 1997-04-15 2002-04-11 Charles Nicolette Cell fusions and methods of making and using the same
IL155514A0 (en) * 2000-10-20 2003-11-23 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526622A (ja) * 1994-07-18 2001-12-18 シドニー キンメル キャンサー センター インビボでの腫瘍細胞免疫を高めるための組成物および方法
JP2002501377A (ja) * 1997-04-15 2002-01-15 ダナ−ファーバー キャンサー インスティテュート インク． 樹状細胞ハイブリッド
WO2001059073A2 (en) * 2000-02-11 2001-08-16 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids

Also Published As

Publication number Publication date
WO2004057968A1 (en) 2004-07-15
CA2508209A1 (en) 2004-07-15
IL169124A0 (en) 2007-07-04
US20040115224A1 (en) 2004-06-17
EP1583424A4 (en) 2006-12-27
EP1583424A1 (en) 2005-10-12
AU2003301023A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
Lambert et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity
Panelli et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
Mukherjee et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer
Wang et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines
RU2313365C2 (ru) Фармацевтическая композиция для индукции иммунной реакции у человека
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
Wu et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas
CN101511384A (zh) 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
EP1368061B1 (en) Fusion cells and cytokine compositions for treatment of disease
JP2017507922A (ja) 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物
Kjaergaard et al. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine
AU2002225990A1 (en) Fusion cells and cytokine compositions for treatment of disease
CN101861163A (zh) 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
JP2006509830A (ja) 癌予防用ハイブリッド細胞ワクチンの調製および投与
EP1130088A1 (en) Hybrid cell vaccines
Weigel et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
US20050180951A1 (en) Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
CN112402596B (zh) 多肽组合物及疫苗
Morse et al. Dendritic cell-based approaches to cancer immunotherapy
Zeng Optimizing immunity against BCR-ABL positive leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907